Serapha Bio
PrivateLast Round
Series A
Jun 23, 2026
Est. Valuation
$303.7M
Company Overview
Serapha Bio operates in Healthcare & Life Sciences and is based in the United States. It was founded in 2026.
Serapha Bio is a biotechnology company developing an investigational in vivo base editing therapy for Alpha-1 Antitrypsin Deficiency (AATD).
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Precision Medicine, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Serapha Bio Comparables
Compare Serapha Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| AIRNA | 89% | |
| Beam Therapeutics | 88% | |
| Frequency Therapeutics | 87% |
For institutional investors. Book with your work email.
Serapha Bio Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Serapha Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Janus Henderson Group | Series A |
| Balyasny Asset Management L.P. | Series A |
| RA Capital Management | Series A |
| LifeSci Venture Partners | Series A |
| Eventide Funds | Series A |
| Logos Capital | Series A |
| Casdin Capital | Series A |
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventOct 26, 2026
Serapha Bio, Inc. attends the ERS Alpha-1 Antitrypsin Conference 2026 in Spain, where Simon Krooss presents interim SERP-01 safety and efficacy data on Oct 23rd-24th '26.
- has_issues_withOct 2, 2026
Beam Therapeutics sues Serapha Bio over the alleged use of trade secrets to develop a gene editor for alpha-1 antitrypsin deficiency in New York on Oct 2nd '26.
For institutional investors. Book with your work email.
Serapha Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Serapha Bio's valuation, stock price, and market status.
Is Serapha Bio a public or private company?
Serapha Bio is a private company.
What is the current stock price of Serapha Bio?
Serapha Bio is a private company, so its shares have no public market price. Caplight tracks Serapha Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Serapha Bio worth (valuation)?
Serapha Bio's valuation is estimated at $303.7M based on funding round data.
Can I buy Serapha Bio stock?
Serapha Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Serapha Bio's last funding round?
Serapha Bio's most recent funding round was Series A on June 23, 2026.
Who are the main investors in Serapha Bio?
Key investors in Serapha Bio include RA Capital Management, RTW Investments.
Will Serapha Bio IPO soon?
No public IPO plans have been announced for Serapha Bio.
How can I track Serapha Bio secondary market activity?
Caplight tracks bids, offers, and trades in Serapha Bio's shares on secondary markets.